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Introduction 
Cefuroxime  is1-acetoxyethyl  ester  of  a  β-lactamase-
stable  cephalosporin.
1  This  second  generation-
cephalosporin is active against a wide range of Gram-
positive and Gram-negative organisms
2 which makes it 
useful  in  treating  a  variety  of  infectionscaused  by  b-
lactam-producing  strains  of  Haemophilus  influenzae, 
Moraxella catarrhalis and Staphylococcus aureus. An 
advantage of cefuroxime over other second-generation 
cephalosporins is that it is effective in the treatment of 
Neisseria  gonorrhea  and  H  influenzae.  It  is 
characterized  by  being  the  only  second-generationce 
phalosporin  which  adequately  penetratesinto  the 
cerebrospinal fluid (CSF).
3 The use of Cefuroxime by 
the oral route requires its administration in the form of 
prodrug,  cefuroxime  axetil.  Since  cefuroxime  is  not 
absorbed  orally,  the  1-acetyloxyethyl  (axetil)  ester  of 
cefuroxime  was  used  to  improve  its  gastrointestinal 
absorption.
4  Oral  route  is  the  selective  method  for 
administration of most of the drugs because of its ease 
and patient compliance.
5 Because of the advantages of 
using  a  suspension  and  high  bioavailability  in 
comparison to other dosage forms (except solutions), in 
this  investigation  the  aim  was  formulating  oral 
cefuroxime axetil suspensions. 
 
Materials and Methods 
Materials 
Cefuroxime  axetil  was  purchased  from  Dana 
Pharmaceutical  Company,  Tabriz,  Iran.  Avicel, 
Colloidal silicon dioxide, Silloidal silicon dioxide were 
purchased  from  Exir  Pharmacrutical  Company, 
Boroujerd,  Iran.  Xanthan,  Ploxamer  were  purchased 
from  Sigma-Aldrich,  Basal,  Switzerland.  All  other 
chemicals  were  purchased  fromMerck,  Darmstadt, 
Germany. 
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Purpose: Cefuroxime is the second generation cephalosporin, which its intravenous and 
oral dosage forms are available. Oral route is the selective method for administration of 
most of the drugs. The aim of this study was formulating ‘for oral’ cefuroxime axetil 
suspensions. Methods:Minitab (ver.15) was used to design the formulations containing 
125  mg  of  cefuroxime  in  5  ml  vehicle.After  selecting  the  acceptable  preparations, 
physical stability tests and other tests such as dissolution rate, pH, zeta potential and 
viscosity  measurement  of  formulations  were  performed.  Results:From  all  33 
formulations,  only  9  were  selected  to  further  investigation.  Considering  no 
sedimentation,  the  sedimentation  volume  was  determined  to  be  1.  The  degrees  of 
flocculation were also equal to 1. All selected formulations released the drug between 
81-100% in 30 minutes which was acceptable according to the USP32 criteria. The 
results of assay test also proved that all formulations contain the drug in acceptable 
range (91-106%). The viscosity curves showed that the systems were pseudo plastic 
and thixotrop. Conclusion: Designed cefuroxime axetil formulations had good qualities 
and could be added as a new product to Iran drug marketing. 
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Formulation of suspensions 
One of the methods for making the suspension, is the 
dispersion of a particle in a vehicle that can be done by 
mechanical instruments or by the use of surfactants that 
contains  three  steps:  a)  wetting  of  particles,  b) 
disintegration of aggregated particles, and c) prevention 
of re-aggregation of particles in the vehicle.
6 
For  suspension  formulation  equivalent  to  125  mg  of 
cefuroxime  was  suspended  in  5  ml  vehicle,  after 
selecting the type and concentration of wetting agent, 
other  ingredients  such  as  flocculating  agents, 
suspending  agents,  preservatives  and  flavors  were 
added.
6  Minitab (ver.15) software was used to design 
the formulations. 
 
Evaluation of physical stability 
Made  formulations  are  then  evaluated  for  physical 
stability tests in which the sedimentation volume (the 
ratio of the final volume of the sediment to the original 
volume of the suspension) and degree of flocculation 
(the  ratio  of  the  ultimate  sediment  volume  of 
flocculated suspension to the ultimate sediment volume 
of deflocculated suspension) were conducted.
7 
 
Assay test 
Prepared formulations wereevaluated by UV system in 
281 wavelengths, for the standard solution 20 mg of the 
drug  was  dissolved  in  50  ml  methanol  and  10.61 
concentration  of  it  was  made  by  dilution  and  the 
absorbance was  read.  For the  assay  solution 5  ml  of 
suspension was dissolved in 50 ml methanol and after 
shaking for 5 minutes 200 ml of medium was added 
and  after  achieving  10.61  concentrations  the 
absorbance was read. 
 
Dissolution test 
For  3  of  each  formulation,  dissolution  test  was 
performedwith USP 2 apparatus (Paddle) in 50 rpm for 
30  minutes.  900  ml  of  medium  (3.7  g  of  monobasic 
sodium  phosphate  and  5.7  g  of  anhydrous  dibasic 
sodium phosphate) was transferred to each vessel and 
the absorbances of the samples were read in maximum 
absorption  wavelength  of  281.  Thenusing  equation 
derived from calibration curve 
(y = 0.0344x + 0.0233   و  R² = 0.9991(the percentage of 
drug release was calculated.
8 
Other  tests,  including  measurement  of  pH,  viscosity 
and zeta potential measurements were performed  and 
finally the best formulationswere selected. 
 
Results 
From all 33 formulations designed in Minitab software, 
only 9 was selected to further investigation that are listed 
in the Table 1. The sedimentation volume was calculated 
to  be  1  in  all  the  suspensions,  therefore  there  was  no 
need to re-dispersion test and the degree of flocculation 
value  was  also  1.  All  selected  formulations  released 
more  than  60%  of  the  drug  (81-100%)  that  was 
acceptable according to the USP32 criteria. In Figure 1 
the  percentage  of  release  in  all  the  formulations  are 
presented. Assay tests also show that the amount of drug 
in all formulations are in the range of 91-106% and all 
are acceptable (Table 2). After calculating the viscosity, 
the curves of viscosityagainst shear ratewere plotted. A 
sample of these curves is shown in Figure 2. 
 
 
Figure 1. Percentage of release for all selected formulations 
 
Figure 2. A sample viscosity curve for formulated suspension 
 
Table 1. Composition of selected formulations designed in Minitab (ver.15) 
Formulations  Drug%  Glucose%  Avicel%  Polaxamer% 
Silloidal silicon 
dioxide%  Xanthan% 
Colloidal silicon 
dioxide% 
9  20  50  12.5  0.55  0.275  0.175  16.5 
26  20  50  5  1  0.05  0.05  23.9 
27  20  50  5  1  0.5  0.3  23.2 
28  20  50  5  0.1  0.05  0.05  24.35 
29  20  50  5  0.1  0.05  0.3  24.55 
30  20  50  5  1  0.05  0.3  23.65 
31  20  50  5  0.1  0.05  0.05  24.8 
32  20  50  5  1  0.5  0.05  23.45 
33  20  50  5  0.1  0.5  0.3  24.1 
  
|   95 
Cefuroxime axetil suspension formulation 
 
Advanced Pharmaceutical Bulletin, 2011, 1(2), 93-96  Copyright © 2011 by Tabriz University of Medical Sciences 
Table 2. Results of assay test 
Formulations 
concentration (μg/ml) 
sample 1 
concentration (μg/ml) 
sample 2 
concentration (μg/ml) 
sample 3 
Percent of labeled 
amount 
9  9.97  11.05  10.29  98.36 
26  13.26  9.77  10.29  104.66 
27  10.03  9.53  9.68  91.87 
28  9.26  10.11  10.48  93.78 
29  10.35  10.93  10.46  99.73 
30  10.48  10.44  10.67  100.37 
31  11.08  10.7  10.81  102.37 
32  11.54  11.19  11.25  106.76 
33  11.1  10.58  10.76  101.92 
 
 
Discussion 
General criteria for selecting a suitable suspension can 
be consideredas proper appearance of uniformity and 
homogeneity, the number of low-frequency shaking for 
the complete distribution, the high volume of sediment, 
no  crystal  growth  and  appropriate  pour  ability. 
According to  these  properties  a  general  discussion  is 
presented. 33 formulations were designed with Minitab 
(ver.15)  software  and  only  9  were  pourable  and  had 
ideal characteristics to continue more other tests. There 
was  no  sediment  in  selected  formulations  and  the 
sediment volume was 1 for all of them so there was no 
need  for  re-dispersion  test  and  the  degree  of  the 
flocculation was also 1 that was probably  because of 
the  high  viscosity  of  the  system.pH  measurement 
indicated that all the suspensions' pH were between 5 -
6  that  was  acceptable  according  to  the 
pharmacopeia.Release  test  approved  that  all  the 
formulations  released  drug  more  than  60%  in  30 
minutes.  According  to  the  curve  each  formulation 
released  95.44,  96.82,  79.10,  81.10,  89.69,  92.62, 
88.14, 99.28, and 89.69 in 30 minutes. The assay test 
showed  that  all  the  formulations  contain  drug  in 
acceptable range according to the pharmacopeia and all 
contains between 91-106%. 
According to the viscosity curves, the suspensions were 
pseudo plastic, i.e., the viscosity decreases as the shear 
rate increases. This is probably because of xanthan and 
sodium  carboxymethyl  cellulose  (exists  in  the  avicel 
RC-591  in  the  amount  between  8-13%) 
9which  give 
pseudo plastic property to the vehicle. Considering the 
differences of the viscosity in up and down curves the 
thixotropy of the system is obvious so the vehicle was 
pseudo  plastic  and  thixotrop.  Also  the  system  was 
found to be time-depended. That means after a while 
takes  the  stress  off,  the  initial  viscosity  of  the 
suspension is achievedand that’s a good chance to pour 
the suspension after each re-dispersion which is one of 
the most important characteristics in suspensions, also 
because of the high viscosity of the system despite of 
having flocculated particles in the vehicle according to 
Stokes's law the sedimentation rate was low.
4 
The charge of the particles effects their distribution in 
the  environment  and  increasesthe  concentration  of 
opposite  charge  on  the  surface  close  to  them  which 
produces  electric  double  layer.  The  potential  of  the 
moving  layer  around  each  particle  is  called  zeta 
potential.  Quantity  of  zeta  potential  can  indicate  the 
potential  stability  of  the  colloidal  system,  if  the 
particles have a large positive or negative zeta potential 
they will have a tendency to repel each other and in too 
low zeta potentials particles will accumulate and attract 
each other.Overall, the borderline between stable and 
unstable  suspensions  is  usually  considered  zeta 
potentials between + 30 mv or - 30 mv means those 
particles which have zeta potential more than +30 or 
lower  than  -30  mv  considered  stable.
10,11  In  this 
investigation  all  the  formulations  had  zeta  potential 
lower  than  -30  mv  but  all  of  them  were  stable  so  it 
seems that mechanisms other than the zeta potential of 
the  particles  is  involved  in  the  formulation  of  stable 
formulations In other words, polymer bridging was the 
main  mechanism  for  controlled  flocculation  in  the 
present work. 
 
Conclusion 
According to the obtained results and considering the 
ideal  characteristics  of  prepared  suspension 
formulations, this product can be added todrug market. 
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